New ‘promising medicines’ fund may incentivise commercialisation of high price drugs with weak evidence on clinical benefits
A new fund to fast-track patient access to potentially valuable new medicines may incentivise the pharmaceutical industry to develop high priced drugs for rare diseases with weak evidence […]
